Prophylactic efficacy of the mucosal cytoprotective agent teprenone and the proton pump inhibitor rabeprazole against gastroduodenal lesions caused by piroxicam: controlled trial study.

The effect of teprenone, a cytoprotective agent and rabeprazole, a proton pump inhibitor (PPI), in preventive mucosal damages caused by piroxicam was evaluated in a controlled prospective study in 30 rheumatic patients requiring NSAIDs. Piroxicam capsules at a clinical standard dose of 20 mg/day were administered in 30 patients for 2 weeks and 20 patients were randomly assigned to receive either rabeprazole 10 mg once daily or teprenone 3 times daily for 2 weeks, along with piroxicam. Gastric damage was slightly less tendency in teprenone group compared with the only administered piroxicam group. However, duodenal ulcers developed in 2 cases in both groups with no intergroup difference in preventive effect. Among 10 patients given 10 mg of rabeprazole along with piroxicam, there was a significantly lower incidence of development of gastroduodenal damage in rabeprazole administered group compared with patients given only piroxicam, which suggested that PPI is as effective in suppressing NSAID induced acute gastroduodenal lesions.